Trinity Biotech plc announced on August 12, 2025, compelling positive clinical trial results demonstrating a major technical breakthrough for its next-generation continuous glucose monitoring (CGM) technology, CGM+. For the first time, trial data confirmed that Trinity Biotech’s redesigned proprietary needle-free glucose sensor delivers accurate glucose readings across a full 15-day wear period without the need for finger-stick calibration. This achievement de-risks the commercial pathway for the platform.
The elimination of finger-stick calibration was achieved through a combination of sensor design modifications, refined signal processing, and proprietary enhancements to sensor operation. This brings the glucose sensor in line with the standards of market leaders, but with a highly differentiated product architecture. The CGM+ platform promises to be more affordable, reusable, and sustainable, while also supporting the single device integration of heart activity, body temperature, and physical activity data.
CEO John Gillard stated that this milestone represents the most significant technical achievement since the company began redevelopment of its acquired CGM technology. The clinical validation of the calibration-free sensor is a critical step toward commercialization of the CGM+ platform. The global CGM market is projected to grow from approximately $13 billion in 2025 to $28 billion by 2030, and Trinity Biotech's differentiated platform is poised to expand access to millions of people.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.